Allene Diaz leads AMD Consulting, a new product strategy and portfolio management consulting practice where she currently serves as Senior Advisor to Xilio Therapeutics.
Ms. Diaz was Senior Vice President, R&D Portfolio Management at GlaxoSmithKline until June 2020. From 2015 to 2019, she served as Senior Vice President of Global Commercial Development and Program Strategy and as a member of the Executive Leadership Team at TESARO Inc.
Prior to joining TESARO, Ms. Diaz held a variety of roles in the EMD Serono and Merck Serono divisions of Merck KGaA, including Senior Vice President, Managed Markets, Senior Vice President, Head of U.S. Oncology Commercial, Vice President, Oncology Marketing and Head of Global Strategic Planning.
Earlier in her career, Ms. Diaz held management, operating, sales, and medical affairs roles at various biopharmaceutical companies, including Pfizer, Parke-Davis, Biogen, and Amylin Pharmaceuticals, among others. She has contributed to the global development, launch and/or commercialization of multiple transformative products across several therapeutic areas.
She serves on the boards of directors of Mersana Therapeutics, Allena Pharmaceuticals and BCLS Acquisition Corporation. Ms. Diaz served on the board of directors of Erytech Pharma SA from 2016 to 2019.
What is Allene M. Diaz's net worth?
The estimated net worth of Allene M. Diaz is at least $442,645.92 as of August 1st, 2023. Ms. Diaz owns 12,676 shares of Ionis Pharmaceuticals stock worth more than $442,646 as of December 30th. This net worth approximation does not reflect any other assets that Ms. Diaz may own. Learn More about Allene M. Diaz's net worth.
How do I contact Allene M. Diaz?
Has Allene M. Diaz been buying or selling shares of Ionis Pharmaceuticals?
Allene M. Diaz has not been actively trading shares of Ionis Pharmaceuticals during the last ninety days. Most recently, Allene M. Diaz sold 657 shares of the business's stock in a transaction on Tuesday, August 1st. The shares were sold at an average price of $41.05, for a transaction totalling $26,969.85. Following the completion of the sale, the director now directly owns 12,676 shares of the company's stock, valued at $520,349.80. Learn More on Allene M. Diaz's trading history.
Who are Ionis Pharmaceuticals' active insiders?
Ionis Pharmaceuticals' insider roster includes Joseph Baroldi (EVP & Chief Business Officer), C. Bennett (EVP), Spencer Berthelsen (Director), Brian Birchler (EVP), Onaiza Cadoret-Manier (EVP), Breaux Castleman (Director), Stanley Crooke (Chairman), Allene Diaz (Director), Richard Geary (EVP), Elizabeth Hougen (CFO), Joseph Klein, III (Director), Brett Monia (CEO), Frederick Muto (Director), Patrick O'Neil (EVP), B. Parshall, Esq. (Director), Eugene Schneider (EVP), and Eric Swayze (EVP). Learn More on Ionis Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Ionis Pharmaceuticals?
During the last year, Ionis Pharmaceuticals insiders bought shares 1 times. They purchased a total of 5,000 shares worth more than $181,100.00. During the last year, insiders at the sold shares 19 times. They sold a total of 134,367 shares worth more than $6,607,085.40. The most recent insider tranaction occured on December, 23rd when Director Michael R Hayden bought 5,000 shares worth more than $181,100.00. Insiders at Ionis Pharmaceuticals own 2.7% of the company.
Learn More about insider trades at Ionis Pharmaceuticals. Information on this page was last updated on 12/23/2024.
